Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial. (2025). SKIN The Journal of Cutaneous Medicine, 9(2), s525. https://doi.org/10.25251/skin.10.supp.525